These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 21960457)

  • 1. Treatment discontinuation in patients with very early rheumatoid arthritis in sustained simplified disease activity index remission after synthetic disease-modifying anti-rheumatic drug administration.
    Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Iwamoto N; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
    Mod Rheumatol; 2012 Jun; 22(3):346-52. PubMed ID: 21960457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
    Hørslev-Petersen K; Hetland ML; Ørnbjerg LM; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2016 Sep; 75(9):1645-53. PubMed ID: 26489704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
    Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Aramaki T; Nakashima M; Fujikawa K; Tsukada T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
    Mod Rheumatol; 2012 Apr; 22(2):195-201. PubMed ID: 21898075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting.
    Vázquez I; Graell E; Gratacós J; Cañete JD; Viñas O; Ercilla MG; Gómez A; Hernández MV; Rodríguez-Cros JR; Larrosa M; Sanmartí R
    Clin Exp Rheumatol; 2007; 25(2):231-8. PubMed ID: 17543147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CIMESTRA study: intra-articular glucocorticosteroids and synthetic DMARDs in a treat-to-target strategy in early rheumatoid arhtritis.
    Hetland ML; Hørslev-Petersen K
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S44-9. PubMed ID: 23079125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study.
    Hetland ML; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Svendsen A; Pedersen JK; Skjødt H; Lauridsen UB; Ellingsen T; Hansen GV; Lindegaard H; Vestergaard A; Jurik AG; Østergaard M; Hørslev-Petersen K;
    Ann Rheum Dis; 2008 Jun; 67(6):815-22. PubMed ID: 17878209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
    Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
    Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
    Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
    Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.
    Kuijper TM; Luime JJ; de Jong PH; Gerards AH; van Zeben D; Tchetverikov I; de Sonnaville PB; van Krugten MV; Grillet BA; Hazes JM; Weel AE
    Ann Rheum Dis; 2016 Dec; 75(12):2119-2123. PubMed ID: 27283332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
    Heimans L; Wevers-de Boer KV; Visser K; Goekoop RJ; van Oosterhout M; Harbers JB; Bijkerk C; Speyer I; de Buck MP; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
    Ann Rheum Dis; 2014 Jul; 73(7):1356-61. PubMed ID: 23716067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a magnetic resonance imaging-guided treat-to-target strategy on disease activity and progression in patients with rheumatoid arthritis (the IMAGINE-RA trial): study protocol for a randomized controlled trial.
    Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg BJ; Boesen M; Hetland ML; Christensen R; Møller J; Krogh NS; Stengaard-Pedersen K; Østergaard M
    Trials; 2015 Apr; 16():178. PubMed ID: 25896862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial.
    Hetland ML; Stengaard-Pedersen K; Junker P; Østergaard M; Ejbjerg BJ; Jacobsen S; Lottenburger T; Hansen I; Tarp U; Andersen LS; Svendsen A; Pedersen JK; Lauridsen UB; Ellingsen T; Lindegaard H; Pødenphant J; Vestergaard A; Jurik AG; Hørslev-Petersen K;
    Ann Rheum Dis; 2010 Oct; 69(10):1789-95. PubMed ID: 20444751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis.
    Mäkinen H; Kautiainen H; Hannonen P; Möttönen T; Leirisalo-Repo M; Laasonen L; Korpela M; Blåfield H; Hakola M; Sokka T
    J Rheumatol; 2007 Feb; 34(2):316-21. PubMed ID: 17183623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms.
    Ajeganova S; van Steenbergen HW; van Nies JA; Burgers LE; Huizinga TW; van der Helm-van Mil AH
    Ann Rheum Dis; 2016 May; 75(5):867-73. PubMed ID: 25972519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of bone edema with the progression of bone erosions quantified by hand magnetic resonance imaging in patients with rheumatoid arthritis in remission.
    Lisbona MP; Pàmies A; Ares J; Almirall M; Navallas M; Solano A; Maymó J
    J Rheumatol; 2014 Aug; 41(8):1623-9. PubMed ID: 24986851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.